Navigation Links
AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Date:4/30/2008

QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Prof. Frans M.J. Debruyne, M.D., Ph.D., Chairman and CEO of Andros Men's Health Institutes in The Netherlands, won the award for Best Poster Presentation in a Poster Session at the 23rd Annual European Association of Urology Meeting, which was held March 26-28, 2008 in Milan, Italy. Titled "LHRH antagonist cetrorelix for symptomatic BPH: Prolonged improvement beyond end of treatment in placebo-controlled trials." FMJ Debruyne, A.A. Gres, A. Bantschev, M. Tzvetkov, K. Grdovic, the poster referred to previously disclosed results from two Phase 2 trials with cetrorelix in benign prostatic hyperplasia (BPH), which showed a prolonged duration of effect extending far beyond the end of the short-term treatment course.

Prof. Jurgen Engel, Ph. D., Executive Vice President, Scientific Affairs at AEterna Zentaris commented, "We would like to congratulate Professor Debruyne for this prestigious award which acknowledges his significant contribution to the quality and achievements of our drug development program with cetrorelix in BPH. The data observed in these Phase 2 trials warranted our current extensive Phase 3 program with cetrorelix in this same indication and we look forward to presenting the results in Q3 2009, as stated previously. We believe cetrorelix could provide a novel, efficient, convenient and safe treatment for the millions of men with BPH."

THE POSTER

Introduction and Objectives

Preliminary studies indicated prolonged, unmaintained improvement in signs and symptoms of BPH after short courses of cetrorelix. Tw
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Announces Changes to its Management Team
4. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
5. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
6. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
7. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , LONDON, November 30 /PRNewswi... company, was named Europe,s fastest growing,Biote...pany in the Deloitte,2009 Technology Fast 500 for ...This annual ranking is based on a companies, five-...d a rate of 8,318% over this period. This,achievem...
(Date:11/28/2009)... The Vanuatu National Advisor...Second National Communication (SNC) Project in col...s and CLIMsystems Ltd. of New Zealand have generat...esults that will form the background for the count...mework Convention on Climate Change (UNFCCC). , ...
(Date:11/27/2009)... A mechanised blue dye test ...to packaging quality assurance one step closer for...ntact leak testing machine developed by Sepha ... installed in several local and global pharma-comp...ddress quality assurance and productivity improvem...
(Date:11/25/2009)... , BOSTON, Nov. 25 Biot...N1 virus, genomic data from the 1918 pandemic thro...current H1N1 pandemic, today issued its latest bio... that the lethality of the H1N1 ("Swine Flu") viru...ng the virus,s current outbreak in the spring of 2...
Breaking Biology Technology:ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
...s Miller, CEO Workflow and Solutions Division, Sie...vent Keynote Speaker, PHILADELPHIA, Jan. 28 Rece...molecular imaging, molecular diagnostics,and infor...ls capable of,assessing and treating a growing num...ls provide physicians with an understanding of ind...
...AIN VIEW, Calif., Jan. 28 Clontech Laboratories,I... today announced the,imminent (February 20, 2008) ...featured in the April issue of Clontechniques, the...researchers at Stanford University and,licensed fr...technology to,regulate the amount of protein of in...
..., Pa., Jan. 28 BioTrends Research Group, Inc.,rel... Publication, a,syndicated report offering compreh... and bone and mineral metabolism in Chronic Kidney...o an online survey, completed by,305 clinical neph...e anemia market, the vast majority of nephrologist...
Other Biology Technology:The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 2The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 3The Dark Report and Siemens Introduce the World's First Integrated Molecular Summit 4Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems 2BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2
(Date:11/26/2009)...antlers, red deer have been caught in the hunters,...much more than decorative. They are lethal weapons...rey, from The University of York, UK, has been int...er half a century and has become fascinated by the...anding collaboration with Tomas Landete-Castillejo...
(Date:11/26/2009)... Staphylococcus Aureus ) and other drug-resistant ...e plasma prototype devices have been developed to ... cocktails. , Two prototype devices have been de... skin (e.g. hands and feet) in hospitals and publi...and another to shoot bacteria-killing agents into ...
(Date:11/25/2009)... the Cell Death Research Laboratory in the Univers...rded the prestigious Johnson & Johnson Focused Fun... brain cell damage in Parkinson,s disease. The awa...pport of innovation and excellence in science, was...er this month at an event at the Hyatt Regency Hot...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution 53788 1XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution 53788 2State Regulation of Massage Therapy Will Improve Public Health Safety 53783 1State Regulation of Massage Therapy Will Improve Public Health Safety 53783 2State Regulation of Massage Therapy Will Improve Public Health Safety 53783 3NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 1NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 2NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 3NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 4
... lowly sea slug, "Elysia chlorotica," may not seem... fooled: it behaves like a plant and is solar-powe... been studying these tiny creatures for the past d...niversities, has identified a possible cause of th...sor James Manhart is a member of a research group ...
...hose who consume fewer calories during flu season ...s, according to research by Michigan State Univers...dner. , In a study published in the November issu...at mice with a calorie-restricted diet were more l...n than mice with a normal diet. Caloric restrictio...
...nanced by NWO, has discovered a new mechanism for ...y hot and acidic conditions. The results of the re...o the functioning of the human body. The research ...e of the American National Academy of Sciences. Th... a Rubicon grant from NWO in 2006 to gain experien...
Other Biology News:Solar-powered sea-slugs live like plants, prof says 2Feed a cold, feed a fever: Research shows calorie cut makes it harder to fight flu 2Proteins strangle cell during division 2
Acridinium NHS ester from Cayman Chemical
...olor real-time PCR detection system holds 48 x 0.2... LEDs independently excites fluorescence (470-500 ...des detects emitted light (523-543 nm and 540-700 ...e Peltier heat pumps provide superb thermal perfor...
... making flow cytometry accessible to anyone in the... latest addition to Guavas on-demand microcapillar... easy to use, surprisingly affordable, very compac...or detection. The Guava EasyCyte Mini has all of t...
...t designed to hold up to 6 strain chambers with pr...asy to use design ensures that cells grow over lon...r compression. This unit allows you to control the...unique strain settings. The instrument fits in a s...
Biology Products: